Letter by Golomb and Hall Regarding Article, "Temporary Emergency Guidance to US Stroke Centers During the COVID-19 Pandemic" by Golomb, Meredith R. & Hall, Graham C.
Stroke
Stroke is available at www.ahajournals.org/journal/str
Stroke. 2020;51:00–00. DOI: 10.1161/STROKEAHA.120.030251 July 2020  1
For Disclosures, see page xxx.
© 2020 American Heart Association, Inc. 
LETTER TO THE EDITOR
Letter by Golomb and Hall Regarding Article, “Temporary Emergency Guidance 
to US Stroke Centers During the COVID-19 Pandemic”
Meredith R. Golomb , MD, MSc; Graham C. Hall, MD
To the Editor:
We read with interest the article, "Temporary Emer-
gency Guidance to US Stroke Centers During the COVID-
19 Pandemic."1 These guidelines cited 2 papers from 
Wuhan China which were initially posted online.2,3 Both 
papers reported stroke in ≈6% of hospitalized patients 
with coronavirus disease 2019 (COVID-19). Most of the 
patients had ischemic stroke, but both series reported a 
single patient each with intracranial hemorrhage. These 
patients were older and often had predisposing risk fac-
tors, such as hypertension, diabetes mellitus, smoking, and 
history of cerebrovascular disease. Most of the patients 
had stroke an average of 10 days after COVID-19 onset. 
The guidelines cite the work of Guo et al,4 suggesting that 
hypercoagulable states due to acute infection and car-
diac damage caused by COVID-19 may be some of the 
mechanisms by which COVID-19 causes stroke. Throm-
bocytopenia has been reported in 5% to 41% of patients 
with COVID-19, usually in those who are severely ill.5
However, in some cases, stroke may be the symptom that 
brings a patient with COVID-19 to the emergency room. We 
report a 66-year-old nonsmoking male with past medical 
history of remote cardiac stents on daily baby aspirin. He pre-
sented to the Emergency Department with a 5-day history of 
low-grade fever and 1-day history of coughing. A particular 
severe round of coughing was followed by rapid ascending 
numbness and weakness. Upon reaching the Emergency 
Department, the patient was quadriplegic, C5 American 
Spinal Injury Association  B. Magnetic resonance imaging 
of cervical spine revealed an extensive posterior epidural 
hemorrhage noted from C2 through T1, most pronounced 
at the C5-C6 level, causing mass effect and cord compres-
sion. Complete blood cell count revealed platelet count of 
105; fibrinogen, 259. Prothrombin time and partial thrombo-
plastin time were 1.13 and 26.2. He was taken emergently 
to the operating room for C4-C7 cervical laminectomy for 
evacuation of epidural hematoma. Significant bleeding was 
encountered, and platelets were transfused. No vascular 
malformation was noted on direct visualization. Postopera-
tively, he was extubated and briefly required oxygen via nasal 
cannula. Nasopharyngeal swabs taken on presentation were 
reported positive for COVID-19 on hospital day 8. Hematol-
ogy was consulted and found no other source for his coag-
ulopathy. By hospital day 16, he was able to walk 50 feet 
with rolling walker but required Foley catheter for persistent 
urinary retention. The patient was released to rehabilitation 
on hospital day 16, after he was documented to be asymp-
tomatic from COVID-19 for 14 days.
For this patient, we suspect the pressure from severe 
coughing and the drop in platelet count due to COVID-19 
combined with platelet dysfunction from aspirin use all con-
tributed to his spinal stroke. We suggest that rare patients 
may be at risk for hemorrhagic stroke as a complication of 
COVID-19 and that screening for COVID-19 be considered 
as part of the stroke workup during the current pandemic.
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